Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $49

Benzinga · 07/22/2024 13:33
Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $44 to $49.